Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Carcinoma, Endometrioid × temsirolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Renal Cell 27 Neoplasm Metastasis 13 Neoplasms 12 Glioblastoma 11 Sarcoma 10 Kidney Neoplasms 10 Endometrial Neoplasms 10 Breast Neoplasms 10 Prostatic Neoplasms 9 Melanoma 9 Lymphoma, Mantle-Cell 9 Brain Neoplasms 9 Multiple Myeloma 7 Lymphoma, Non-Hodgkin 7 Ovarian Neoplasms 6 Carcinoma, Hepatocellular 6 Precursor Cell Lymphoblastic Leukemia-Lymphoma 5 Gliosarcoma 5 Glioma 5 Central Nervous System Neoplasms 5 Carcinoma, Non-Small-Cell Lung 5 Uterine Cervical Neoplasms 4 Unspecified Adult Solid Tumor, Protocol Specific 4 Rhabdomyosarcoma 4 Recurrence 4 Pancreatic Neoplasms 4 Osteosarcoma 4 Oligodendroglioma 4 Lymphoma, Large B-Cell, Diffuse 4 Lymphoma, Follicular 4

Interventions

Nivolumab 3 Specimen Handling 2 Paclitaxel 2 Magnetic Resonance Spectroscopy 2 Ipilimumab 2 Carboplatin 2 CTLA-4 Antigen 2 temsirolimus 1 sintilimab 1 serabelisib 1 sapanisertib 1 rucaparib 1 pembrolizumab 1 palbociclib 1 olaparib 1 durvalumab 1 defactinib 1 ceralasertib 1 cabozantinib 1 adavosertib 1 Therapeutics 1 Taxes 1 Restraint, Physical 1 Radiation, Ionizing 1 Radiation 1 RO5126766 1 Platinum 1 Megestrol Acetate 1 Medroxyprogesterone Acetate 1 Hysterectomy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02093598 2020-11-27

POEM

MedSIR

Phase 2 Completed

Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon ⚡